Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2021

01-10-2021 | Nosocomial Infection | Brief Report

Absence of Toxemia in Clostridioides difficile Infection: Results from Ultrasensitive Toxin Assay of Serum

Authors: Rebecca Sprague, Karolyne Warny, Nira Pollock, Kaitlyn Daugherty, Qianyun Lin, Hua Xu, Christine Cuddemi, Caitlin Barrett, Xinhua Chen, Alice Banz, Aude Lantz, Kevin W. Garey, Anne J. Gonzales-Luna, Carolyn D. Alonso, Javier A. Villafuerte Galvez, Ciarán P. Kelly

Published in: Digestive Diseases and Sciences | Issue 10/2021

Login to get access

Abstract

Clostridioides difficile infection (CDI) is caused by Toxins A and B, secreted from pathogenic strains of C. difficle. This infection can vary greatly in symptom severity and in clinical presentation. Current assays used to diagnose CDI may lack the required sensitivity to detect the exotoxins circulating in blood. The ultrasensitive single molecule array (Simoa) assay was modified to separately detect toxin A and toxin B in serum with a limit of detection at the low picogram level. When applied to a diverse cohort, Simoa was unable to detect toxins A or B in serum from patients with CDI, including many classified as having severe disease. The detection of toxin may be limited by the inference of antitoxin antibodies circulating in serum. This result does not support the hypothesis that toxemia occurs in C. difficile infection, conflicting with the findings of other published reports.
Literature
1.
go back to reference Guh AY, Mu Y, Winston LG, et al. Trends in U.S. burden of Clostridioides difficile infection and outcomes. New Engl J Med. 2020;382:1320–1330.CrossRef Guh AY, Mu Y, Winston LG, et al. Trends in U.S. burden of Clostridioides difficile infection and outcomes. New Engl J Med. 2020;382:1320–1330.CrossRef
2.
go back to reference Schutze GE, Willoughby RE. Clostridium difficile infection in infants and children. Pediatrics. 2013;131:196–200.CrossRef Schutze GE, Willoughby RE. Clostridium difficile infection in infants and children. Pediatrics. 2013;131:196–200.CrossRef
3.
go back to reference Lessa FC, Winston LG, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:2369–2370.CrossRef Lessa FC, Winston LG, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:2369–2370.CrossRef
4.
go back to reference Fang FC, Polage CR, Wilcox MH. Point-counterpoint: what is the optimal approach for detection of clostridium difficile Infection? J Clin Microbiol. 2017;55:670–680.CrossRef Fang FC, Polage CR, Wilcox MH. Point-counterpoint: what is the optimal approach for detection of clostridium difficile Infection? J Clin Microbiol. 2017;55:670–680.CrossRef
5.
go back to reference Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature. 2010;467:711–713.CrossRef Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature. 2010;467:711–713.CrossRef
6.
go back to reference Dobson G, Hickey C, Trinder J. Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome. Intensive Care Med. 2003;29:1030.CrossRef Dobson G, Hickey C, Trinder J. Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome. Intensive Care Med. 2003;29:1030.CrossRef
7.
go back to reference Qualman SJ, Petric M, Karmali MA, Smith CR, Hamilton SR. Clostridium difficile invasion and toxin circulation in fatal pediatric pseudomembranous colitis. Am J Clin Pathol. 1990;94:410–416.CrossRef Qualman SJ, Petric M, Karmali MA, Smith CR, Hamilton SR. Clostridium difficile invasion and toxin circulation in fatal pediatric pseudomembranous colitis. Am J Clin Pathol. 1990;94:410–416.CrossRef
8.
go back to reference Yu H, Chen K, Wu J, et al. Identification of toxemia in patients with Clostridium difficile infection. PLoS One. 2015;10:e0124235.CrossRef Yu H, Chen K, Wu J, et al. Identification of toxemia in patients with Clostridium difficile infection. PLoS One. 2015;10:e0124235.CrossRef
9.
go back to reference Pollock NR, Banz A, Chen X, et al. Comparison of clostridioides difficile stool toxin concentrations in adults with symptomatic infection and asymptomatic carriage using an ultrasensitive quantitative immunoassay. Clin Infect Dis. 2019;68:78–86.PubMed Pollock NR, Banz A, Chen X, et al. Comparison of clostridioides difficile stool toxin concentrations in adults with symptomatic infection and asymptomatic carriage using an ultrasensitive quantitative immunoassay. Clin Infect Dis. 2019;68:78–86.PubMed
10.
go back to reference Song L, Zhao M, Duffy DC, et al. Development and validation of digital enzyme-linked immunosorbent assays for ultrasensitive detection and quantification of clostridium difficile toxins in stool. J Clin Microbiol. 2015;53:3204–3212.CrossRef Song L, Zhao M, Duffy DC, et al. Development and validation of digital enzyme-linked immunosorbent assays for ultrasensitive detection and quantification of clostridium difficile toxins in stool. J Clin Microbiol. 2015;53:3204–3212.CrossRef
Metadata
Title
Absence of Toxemia in Clostridioides difficile Infection: Results from Ultrasensitive Toxin Assay of Serum
Authors
Rebecca Sprague
Karolyne Warny
Nira Pollock
Kaitlyn Daugherty
Qianyun Lin
Hua Xu
Christine Cuddemi
Caitlin Barrett
Xinhua Chen
Alice Banz
Aude Lantz
Kevin W. Garey
Anne J. Gonzales-Luna
Carolyn D. Alonso
Javier A. Villafuerte Galvez
Ciarán P. Kelly
Publication date
01-10-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2021
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06683-8

Other articles of this Issue 10/2021

Digestive Diseases and Sciences 10/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine